Phase 1/2 Study of TSHA-105 in SLC13A5 Citrate Transporter Disorder Initiated
A Phase 1/2 open-label study is underway to evaluate TSHA-105 for SLC13A5 Citrate Transporter Disorder.
Asset / Drug
Drug and asset intelligence for TSHA-105 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Gene Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.